ILT Antibody (D-6): sc-166549

ILT Antibody (D-6) is a mouse monoclonal IgG2a antibody that detects leukocyte immunoglobulin-like receptor (ILT) in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). ILT proteins play a crucial role in the immune system, particularly in modulating immune responses, as ILT proteins are expressed predominantly on monocytes, B cells, dendritic cells, and natural killer cells. The ILT family is divided into two subfamilies: subfamily A, which includes ILT-1, ILT-6, ILT-7, ILT-8, ILT-11, and LIR-6, functions primarily as stimulatory receptors, while subfamily B, comprising ILT-2, ILT-3, ILT-4, ILT-5, and LIR-8, serves as inhibitory receptors. The structural distinction between these subfamilies is significant; members of subfamily A possess transmembrane regions with charged arginine residues that initiate stimulatory signaling cascades, whereas subfamily B members contain immunoreceptor tyrosine-based inhibitory motifs (ITIMs) that trigger inhibitory pathways. This balance between stimulation and inhibition is vital for maintaining immune homeostasis and preventing overactive immune responses, which can lead to autoimmune diseases. Anti-ILT antibody (D-6) is an essential tool for researchers studying these complex immune mechanisms and their implications in health and disease.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

ILT Antibody (D-6) References:

1. Immunoglobulin-like transcript 3: A crucial regulator of dendritic cell function.  |  Vlad, G., et al. 2009. Hum Immunol. 70: 340-4. PMID: 19275918
2. Expression of immunoglobulin-like transcript (ILT)2 and ILT3 in human gastric cancer and its clinical significance.  |  Zhang, Y., et al. 2012. Mol Med Rep. 5: 910-6. PMID: 22246571
3. Immunoglobulin-like transcript receptors on human dermal CD14+ dendritic cells act as a CD8-antagonist to control cytotoxic T cell priming.  |  Banchereau, J., et al. 2012. Proc Natl Acad Sci U S A. 109: 18885-90. PMID: 23112154
4. Pediatric tolerogenic DCs expressing CD4 and immunoglobulin-like transcript receptor (ILT)-4 secrete IL-10 in response to Fc and adenosine.  |  Franco, A., et al. 2018. Eur J Immunol. 48: 482-491. PMID: 29244203
5. Immunoglobulin-Like Transcript 5 Inhibits Macrophage-Mediated Bacterial Killing and Antigen Presentation During Sepsis.  |  Ming, S., et al. 2019. J Infect Dis. 220: 1688-1699. PMID: 31250008
6. First-in-Class Anti-immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors.  |  Siu, LL., et al. 2022. Clin Cancer Res. 28: 57-70. PMID: 34598945
7. Tumor-derived immunoglobulin like transcript 5 induces suppressive immunocyte infiltration in colorectal cancer.  |  Shi, W., et al. 2022. Cancer Sci. 113: 1939-1954. PMID: 35377522
8. Immunoglobulin-like transcript 2 blockade restores antitumor immune responses in glioblastoma.  |  Lorenzo-Herrero, S., et al. 2023. Cancer Sci. 114: 48-62. PMID: 36082628
9. Immunoglobulin-like transcript 2 as an impaired anti-tumor cytotoxicity marker of natural killer cells in patients with hepatocellular carcinoma.  |  Sakata, T., et al. 2024. Front Immunol. 15: 1389411. PMID: 38638429
10. Isotypic variation of novel immunoglobulin-like transcript/killer cell inhibitory receptor loci in the leukocyte receptor complex.  |  Torkar, M., et al. 1998. Eur J Immunol. 28: 3959-67. PMID: 9862332

The preferred ILT-2 antibody is ILT-2 Antibody (VMP55): sc-20065.